An Open-Label Pharmacokinetics and Safety Study of Talazoparib
NCT02997163
ABOUT THIS STUDY
FOR MORE INFORMATION
Contact a representative by phone, email, or visiting the study website. Please see the references below:
Pfizer Clinical Trials Contact Center
1-800-718-1021
1. Signed and dated informed consent form (by the patient or a legally acceptable representative as per the local regulations) obtained prior to initiation of any study-specific procedure and treatment.
2. Female or male of at least 18 years of age.
3. Histologically or cytologically confirmed advanced solid tumor with no available standard approved treatment options in the opinion of the Investigator
4. Eastern Cooperative Oncology Group (ECOG) Performance status (PS) ≤ 2.
5. Expected life expectancy of ≥ 3 months.
6. Able to swallow the study drug (no contra indication to oral agents).
7. Renal function at screening and enrollment as defined by the Modification of Diet in Renal Disease (MDRD) equation.
8. Patient has had no clinically significant change in renal status within 3 months prior to screening, according to Investigator's review of clinical patient records.
9. Patient is not currently on hemodialysis and/or peritoneal dialysis for management of chronic kidney disease or acute failure/conditions.
10. Patient has no unstable renal function, defined as a change in estimated glomerular filtration rate (eGFR) (calculated with the MDRD equation) of > 25% for patients with mild and moderate renal impaired or as a change in eGFR > 30% for patients with severe renal impaired, from screening to enrollment.
11. Adequate other organ function at screening and enrollment.
12. Female patients of childbearing potential must have a negative serum pregnancy test at screening, and must agree to use a highly effective birth control method from the time of the first dose of study drug through 45 days after the last dose of study drug.
13. Male patients must agree to use a condom when having sex with a pregnant woman or with a non-pregnant female partner of childbearing potential, from 21 days before the first dose of study drug through 105 days after last dose of study drug.
14. Female patients must not be breastfeeding at screening nor during the study participation until 45 days after the last dose of study drug.
15. Willingness and ability to comply with scheduled visits, treatment plan, laboratory tests, and other trial procedures.
1. Treatment within 14 days or five half lives prior to enrollment with any type of
systemic anticancer-therapy or any investigational drug, whichever is longer.
2. Have not recovered (recovery is defined as CTCAE grade ≤ 1) from the acute toxicities
of previous anticancer standard or investigational therapy, except treatment-related
alopecia or laboratory abnormalities otherwise meeting eligibility requirements.
3. Major surgery within 28 days prior to enrollment.
4. Serious accompanying cardiac disorder.
5. Active known or suspected brain metastasis or active leptomeningeal disease undergoing
or requiring treatment.
6. Symptomatic or impending spinal cord compression or cauda equina syndrome.
7. Has undergone a liver transplant, kidney transplant or nephrectomy.
8. Prior allergic reaction or severe intolerance (meeting the criteria for a serious
adverse event, a grade 3 or 4 AE, or permanent treatment discontinuation) to a poly
ADP ribose polymerase (PARP) inhibitor.
9. Known myelodysplastic syndrome.
10. Seropositive for human immunodeficiency virus (HIV).
11. Any serious or unstable medical condition that interferes with ability to tolerate
treatment or assessments associated with the protocol.
12. Gastrointestinal disorder affecting absorption.
13. Known or suspected hypersensitivity to any of the talazoparib capsule components.
14. Any condition or reason that interferes with ability to participate in the study,
tolerate treatment or assessments associated with the protocol, causes undue risk, or
complicates the interpretation of safety data, in the opinion of the Investigator or
Medical Monitor.
NEED INFO?
Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
- New Lambton Heights, New South Wales
- New Lambton Heights, New South Wales
- Downey, California
- Encinitas, California
- Glendale, California
- Long Beach, California
- Los Angeles, California
- Los Angeles, California
- Santa Ana, California
- Whittier, California
- Whittier, California
- New Haven, Connecticut
- New Haven, Connecticut
- New Haven, Connecticut
- Lake Mary, Florida
- Kansas City, Missouri
- Bronx, New York
- Cincinnati, Ohio
- Cleveland, Ohio
- West Chester, Ohio
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Pittsburgh, Pennsylvania
- Dallas, Texas
- San Antonio, Texas
- Liverpool, New South Wales
- Liverpool, New South Wales
- Washington, District of Columbia
- Los Angeles, California
- Los Angeles, California
- Santa Monica, California
- Aurora, Colorado
- Aurora, Colorado
- Port Saint Lucie, Florida
- Fort Wayne, Indiana
- Fort Wayne, Indiana
- Fort Wayne, Indiana
- Fort Wayne, Indiana
- Lafayette, Indiana
- Cedar Rapids, Iowa
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Boston, Massachusetts
- Detroit, Michigan
- Rochester, Minnesota
- Saint Paul, Minnesota
- Saint Paul, Minnesota
- Saint Paul, Minnesota
- Saint Paul, Minnesota
- Nashville, Tennessee
- Nashville, Tennessee
- Nashville, Tennessee
- San Antonio, Texas
- Salt Lake City, Utah
- Salt Lake City, Utah
- Charlottesville, Virginia
- Charlottesville, Virginia
- Budapest,
Descriptive Information | |||||
---|---|---|---|---|---|
Brief Title ICMJE | An Open-Label Pharmacokinetics and Safety Study of Talazoparib | ||||
Official Title ICMJE | A PHASE I OPEN-LABEL PHARMACOKINETICS AND SAFETY STUDY OF TALAZOPARIB (MDV3800) IN PATIENTS WITH ADVANCED SOLID TUMORS AND NORMAL OR VARYING DEGREES OF RENAL IMPAIRMENT | ||||
Brief Summary | This trial will investigate the pharmacokinetics (PK) and safety of talazoparib in patients with advanced solid tumors and impaired renal function. | ||||
Detailed Description | At the End of the Study, patients with no clinically significant toxicities, no contraindications to continue treatment with talazoparib, and no disease progression (underlying cancer progression) may be eligible to continue talazoparib treatment in a separate open-label extension study after discussion with the Principal Investigator and obtaining Sponsor permission. Sponsor decision to allow the patient to continue dosing with talazoparib in an open-label extension study will be based on potential overall benefit-risk, patient acceptance and other relevant criteria. | ||||
Study Type ICMJE | Interventional | ||||
Study Phase ICMJE | Phase 1 | ||||
Study Design ICMJE | Allocation: Non-Randomized Intervention Model: Parallel Assignment Masking: None (Open Label) Primary Purpose: Treatment | ||||
Condition ICMJE | Advanced Solid Tumors | ||||
Intervention ICMJE | Drug: Talazoparib
Daily oral doses of talazoparib 0.5 mg Other Names:
| ||||
Study Arms ICMJE |
| ||||
Publications * | Durairaj C, Chakrabarti J, Ferrario C, Hirte HW, Babu S, Piha-Paul SA, Plotka A, Hoffman J, Shi H, Wang DD. The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid Tumors. Clin Pharmacokinet. 2021 Mar 9. doi: 10.1007/s40262-020-00983-y. [Epub ahead of print] | ||||
* Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline. | |||||
Recruitment Information | |||||
Recruitment Status ICMJE | Completed | ||||
Actual Enrollment ICMJE | 34 | ||||
Original Estimated Enrollment ICMJE | 24 | ||||
Actual Study Completion Date ICMJE | January 30, 2019 | ||||
Actual Primary Completion Date | January 30, 2019 (Final data collection date for primary outcome measure) | ||||
Eligibility Criteria ICMJE | Inclusion Criteria:
Exclusion Criteria:
| ||||
Sex/Gender ICMJE |
| ||||
Ages ICMJE | 18 Years and older (Adult, Older Adult) | ||||
Accepts Healthy Volunteers ICMJE | No | ||||
Contacts ICMJE | Contact information is only displayed when the study is recruiting subjects | ||||
Listed Location Countries ICMJE | Canada, United States | ||||
Removed Location Countries | |||||
Administrative Information | |||||
NCT Number ICMJE | NCT02997163 | ||||
Other Study ID Numbers ICMJE | MDV3800-01 C3441001 ( Other Identifier: Alias Study Number ) 2016-002536-33 ( EudraCT Number ) | ||||
Has Data Monitoring Committee | No | ||||
U.S. FDA-regulated Product |
| ||||
IPD Sharing Statement ICMJE |
| ||||
Responsible Party | Pfizer | ||||
Study Sponsor ICMJE | Pfizer | ||||
Collaborators ICMJE | Medivation, Inc. | ||||
Investigators ICMJE |
| ||||
PRS Account | Pfizer | ||||
Verification Date | December 2020 | ||||
ICMJE Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP |